Marketgems Earnings Trader- Trading Strong or Weak Earnings Growth

[Profit_Ace]

AGIX! embroiled in controversy this weekend because of a Barron's article quoting the head of the Cleveland clinc, one of the two clinics conducting the CART II trial, as saying that the phase II trial of AGI 1067 is "bogus" and that "the SEC should investigate AGIX". This is a real bizarre turn of events. However this could turn into a nice buying opportunity. If the stock takes a nose dive, you might consider buying some otm October calls (<$1), hoping for a quick recovery (in case AGIX officials counter the charges). If the Nov. otm calls arent much more expensive, I may consider them. But be prepared to lose all your premium if in fact this Dr. Topol has a legitimate case.


http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh85866_2004-10-03_21-15-24_n03...